Bionano Genomics (NASDAQ:BNGO) (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity. These capabilities complement next‐generation sequencing methods by filling critical gaps in detecting large insertions, deletions, inversions, and translocations.
The company’s product portfolio includes the Saphyr instrument, DLS™ (Direct Label and Stain) reagents for consistent labeling performance, and the Bionano Access™ and Bionano Solve™ software suites for data visualization, variant calling and genomic assembly. In addition to direct instrument sales, Bionano offers contract genome mapping services from its service centers, enabling researchers without in-house platforms to access its mapping capabilities. Its customers span academic research institutions, biotechnology and pharmaceutical companies, clinical laboratories and government agencies focused on areas such as cancer genomics, rare disease diagnostics, plant and animal breeding, and translational research.
Founded in 2003 and headquartered in San Diego, California, Bionano Genomics has grown from early development of nanochannel‐based mapping concepts to a commercial enterprise with global reach, serving markets in North America, Europe and the Asia-Pacific region. The company’s leadership team brings together expertise in genomics, engineering and life-science commercialization, guided by President and Chief Executive Officer Erik Holmlin, Ph.D., who has overseen the expansion of the Saphyr platform since its commercial launch in 2017. Bionano continues to advance its technology roadmap with the goal of broadening applications in both research and clinical settings.
